Renal drug transporters and drug interactions

A Ivanyuk, F Livio, J Biollaz, T Buclin - Clinical pharmacokinetics, 2017 - Springer
Transporters in proximal renal tubules contribute to the disposition of numerous drugs.
Furthermore, the molecular mechanisms of tubular secretion have been progressively …

Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management.

F Gutierrez, X Fulladosa, G Barril… - AIDS reviews, 2014 - search.ebscohost.com
Interactions of drugs with renal transporters can reduce the tubular secretion of endogenous
products and affect drug pharmacokinetics, efficacy, and toxicity. This review aims to …

Targeting HIV-1 Reverse transcriptase using a fragment-based approach

M Mansouri, S Rumrill, S Dawson, A Johnson… - Molecules, 2023 - mdpi.com
Human immunodeficiency virus type I (HIV-1) is a retrovirus that infects cells of the host's
immune system leading to acquired immunodeficiency syndrome and potentially death …

Substrates and inhibitors of organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) and therapeutic implications

H Bönisch - Organic cation transporters in the central nervous …, 2021 - Springer
The gene products of the SLC22A gene family (hOCT1, hOCT2, and hOCT3) and of the
SLC29A4 gene (hPMAT or hENT4) are all polyspecific organic cation transporters. Human …

Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies

A Jakimiuk, A Piechal, A Wiercińska-Drapało… - Pharmacological …, 2023 - Springer
The evaluation of dolutegravir based on available preclinical and clinical studies reveals a
risk of central nervous system (CNS) disorders associated with long-term use of the drug …

Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis

AA Reeves, AV Fuentes, J Caballero… - Sexually transmitted …, 2021 - sti.bmj.com
Objective To assess the risk of neuropsychiatric adverse effects (ie, depression, anxiety,
insomnia, dizziness, suicidal behaviour) among patients treated with rilpivirine, dolutegravir …

[HTML][HTML] Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV

MM McLaughlin, AJ Guerrero, A Merker - Drugs in context, 2018 - ncbi.nlm.nih.gov
A review of literature published regarding non-tenofovir antiretroviral agents causing renal
adverse effects was conducted. The literature involving renal adverse effects and …

HIV-1 sanctuary sites—the role of membrane-associated drug transporters and drug metabolic enzymes

SK Whyte-Allman, R Bendayan - The AAPS journal, 2020 - Springer
Despite significant advances in the treatment of human immunodeficiency virus-1 (HIV)
infection with highly active antiretroviral drug therapy, the persistence of the virus in cellular …

[HTML][HTML] Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through …

BJ Heaton, RL Jensen, J Line, CAW David… - Biomedicine & …, 2022 - Elsevier
SLC2A1 mediates glucose cellular uptake; key to appropriate immune function. Our
previous work has shown efavirenz and lopinavir exposure inhibits T cell and macrophage …

MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption

J Reznicek, M Ceckova, Z Ptackova… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Rilpivirine (TMC278) is a highly potent nonnucleoside reverse transcriptase inhibitor
(NNRTI) representing an effective component of combination antiretroviral therapy (cART) in …